Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab.

IF 4.2 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiac Failure Review Pub Date : 2021-05-12 eCollection Date: 2021-03-01 DOI:10.15420/cfr.2020.33
Ava Diarra, Guillaume Gantois, Mouna Lazrek, Basile Verdier, Vincent Elsermans, Hélène Zephir, Benjamin Longère, Xristos Gkizas, Céline Goeminne, Gilles Lemesle, Francis Juthier, Johana Bene, David Launay, Romain Dubois, Sandrine Morell-Dubois, Fanny Vuotto, Anne-Laure Piton
{"title":"Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab.","authors":"Ava Diarra,&nbsp;Guillaume Gantois,&nbsp;Mouna Lazrek,&nbsp;Basile Verdier,&nbsp;Vincent Elsermans,&nbsp;Hélène Zephir,&nbsp;Benjamin Longère,&nbsp;Xristos Gkizas,&nbsp;Céline Goeminne,&nbsp;Gilles Lemesle,&nbsp;Francis Juthier,&nbsp;Johana Bene,&nbsp;David Launay,&nbsp;Romain Dubois,&nbsp;Sandrine Morell-Dubois,&nbsp;Fanny Vuotto,&nbsp;Anne-Laure Piton","doi":"10.15420/cfr.2020.33","DOIUrl":null,"url":null,"abstract":"<p><p>Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e09"},"PeriodicalIF":4.2000,"publicationDate":"2021-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/7e/cfr-07-e09.PMC8135016.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac Failure Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/cfr.2020.33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 3

Abstract

Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利妥昔单抗治疗德维克综合征患者致死性肠病毒相关性心肌炎
肠病毒是一种常见的感染源,也是最常见的中枢神经系统病毒病原体之一。肠道病毒——特别是柯萨奇B型病毒——是已知的心肌炎的病因。利妥昔单抗是一种基因工程嵌合抗cd20单克隆抗体。许多文献报道表明,反复利妥昔单抗治疗后感染的风险更高,包括病毒感染。然而,在利妥昔单抗治疗的背景下,肠病毒相关心肌炎的观察很少。作者描述了一例患有视神经脊髓炎谱系障碍的患者,在接受利妥昔单抗治疗后发展为严重和致命的肠病毒相关性心肌炎,难以鉴别诊断为自身免疫性或巨细胞性心肌炎。本病例强调了在困难的心肌炎病例中,包括心内膜活检在内的完整诊断检查的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
31
审稿时长
9 weeks
期刊最新文献
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action. Pathophysiology of Congestion in Heart Failure: A Contemporary Review. Imaging Advances in Heart Failure. Transcatheter Aortic Valve Replacement is Ready for Most Low-risk Patients: A Systematic Review of the Literature. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1